MCID: GST012
MIFTS: 46

Gastroesophageal Junction Adenocarcinoma

Categories: Cancer diseases, Cardiovascular diseases, Gastrointestinal diseases

Aliases & Classifications for Gastroesophageal Junction Adenocarcinoma

MalaCards integrated aliases for Gastroesophageal Junction Adenocarcinoma:

Name: Gastroesophageal Junction Adenocarcinoma 12 15
Adenocarcinoma of the Gastroesophageal Junction 71
Adenocarcinoma of Cardioesophageal Junction 12
Adenocarcinoma of Gastroesophageal Junction 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4944
NCIt 49 C9296
UMLS 71 C1332166

Summaries for Gastroesophageal Junction Adenocarcinoma

MalaCards based summary : Gastroesophageal Junction Adenocarcinoma, also known as adenocarcinoma of the gastroesophageal junction, is related to helicobacter pylori infection and esophagitis, and has symptoms including abdominal pain An important gene associated with Gastroesophageal Junction Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are ERK Signaling and PAK Pathway. The drugs Gefitinib and Cetuximab have been mentioned in the context of this disorder. Affiliated tissues include lymph node, breast and endothelial, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Gastroesophageal Junction Adenocarcinoma

Diseases related to Gastroesophageal Junction Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 helicobacter pylori infection 30.7 PAK1 IL1B EGFR
2 esophagitis 30.5 VEGFA IL1B EGFR
3 adenocarcinoma 30.3 VEGFA MMP9 KDR FLT1 ERBB2 EGFR
4 gastroesophageal adenocarcinoma 30.3 KDR ERBB2 EGFR CLDN18 CD274
5 neurofibromatosis, type ii 29.9 VEGFA ERBB2 EGFR
6 exanthem 28.6 VEGFA PDCD1 KDR IL1B ERBB2 EGFR
7 esophageal cancer 27.6 VEGFA PDCD1LG2 PDCD1 MMP9 KDR IL1B
8 gastric cancer 27.6 VEGFA SNAI1 SERPINB5 PAK1 MMP9 KDR
9 gastric adenocarcinoma 27.1 VEGFA SERPINB5 PDCD1LG2 PDCD1 MMP9 KDR
10 breast cancer 27.0 VEGFA SNAI1 SERPINB5 PDCD1 PAK1 MMP9
11 neutropenia 10.6
12 dysphagia 10.4
13 breast scirrhous carcinoma 10.4 ERBB2 EGFR
14 mucositis 10.4
15 breast metaplastic carcinoma 10.4 ERBB2 EGFR
16 breast malignant phyllodes tumor 10.3 ERBB2 EGFR
17 gastroesophageal reflux 10.3
18 barrett esophagus 10.3
19 stomatitis 10.3
20 progesterone-receptor negative breast cancer 10.3 ERBB2 EGFR
21 septate uterus 10.3 KDR FLT1
22 ovarian carcinosarcoma 10.2 ERBB2 CD274
23 luminal breast carcinoma a 10.2 SNAI1 ERBB2 EGFR
24 diarrhea 10.2
25 peptic esophagitis 10.2
26 in situ carcinoma 10.2
27 recurrent respiratory papillomatosis 10.2 ERBB2 EGFR CD274
28 submandibular gland cancer 10.2 ERBB2 EGFR
29 vulvar disease 10.2 ERBB2 EGFR CD274
30 cervical adenosquamous carcinoma 10.2 KDR EGFR
31 rectum adenocarcinoma 10.2 ERBB2 EGFR CD274
32 breast angiosarcoma 10.2 VEGFA KDR
33 large cell neuroendocrine carcinoma 10.2 ERBB2 EGFR CD274
34 mammary paget's disease 10.2 ERBB2 EGFR CD274
35 vulva cancer 10.2 ERBB2 EGFR CD274
36 odontogenic myxoma 10.2 VEGFA MMP9
37 oropharynx cancer 10.2 ERBB2 EGFR CD274
38 radiation proctitis 10.2 VEGFA KDR
39 cheilitis 10.1 PDCD1 MMP9 CD274
40 microinvasive gastric cancer 10.1
41 squamous cell carcinoma 10.1
42 barrett's adenocarcinoma 10.1
43 arteriovenous malformation 10.1 VEGFA MMP9 IL1B
44 autoimmune disease of skin and connective tissue 10.1 PDCD1 IL1B CD274
45 decubitus ulcer 10.1 VEGFA MMP9 IL1B
46 angiokeratoma of mibelli 10.1 MMP9 KDR FLT1
47 chronic ulcer of skin 10.1 VEGFA MMP9 IL1B
48 soft tissue sarcoma 10.1 VEGFA EGFR
49 biliary tract cancer 10.1 ERBB2 EGFR
50 eales disease 10.1 VEGFA IL1B

Graphical network of the top 20 diseases related to Gastroesophageal Junction Adenocarcinoma:



Diseases related to Gastroesophageal Junction Adenocarcinoma

Symptoms & Phenotypes for Gastroesophageal Junction Adenocarcinoma

UMLS symptoms related to Gastroesophageal Junction Adenocarcinoma:


abdominal pain

GenomeRNAi Phenotypes related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.19 CD274
2 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.19 EGFR
3 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.19 FLT1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.19 ERBB2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.19 ERBB2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-171 10.19 FLT1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.19 CLDN18
8 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.19 CLDN18
9 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10.19 CD274
10 Increased shRNA abundance (Z-score > 2) GR00366-A-187 10.19 CD274
11 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.19 ERBB2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.19 EGFR
13 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.19 EGFR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.19 CD274
15 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.19 CD274
16 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.19 FLT1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.19 ERBB2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.19 EGFR
19 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.19 CLDN18
20 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.19 KDR
21 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.19 CLDN18
22 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.19 ERBB2 KDR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.19 CLDN18 ERBB2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.19 CLDN18
25 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.19 CD274 EGFR ERBB2 FLT1 KDR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.19 ERBB2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-89 10.19 CLDN18
28 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.19 EGFR
29 Synthetic lethal with gemcitabine GR00225-A 8.8 FLT1 KDR PAK1

MGI Mouse Phenotypes related to Gastroesophageal Junction Adenocarcinoma:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.32 CD274 CLDN18 EGFR ERBB2 FLT1 KDR
2 homeostasis/metabolism MP:0005376 10.3 CD274 CLDN18 EGFR ERBB2 FLT1 IL1B
3 hematopoietic system MP:0005397 10.26 CD274 CLDN18 EGFR FLT1 IL1B KDR
4 mortality/aging MP:0010768 10.25 CD274 EGFR ERBB2 FLT1 IL1B KDR
5 growth/size/body region MP:0005378 10.24 EGFR ERBB2 FLT1 IL1B KDR MMP9
6 cardiovascular system MP:0005385 10.22 EGFR ERBB2 FLT1 IL1B KDR MMP9
7 immune system MP:0005387 10.17 CD274 CLDN18 EGFR FLT1 IL1B KDR
8 nervous system MP:0003631 10 CLDN18 EGFR ERBB2 FLT1 IL1B KDR
9 muscle MP:0005369 9.97 EGFR ERBB2 FLT1 KDR MMP9 PAK1
10 neoplasm MP:0002006 9.87 EGFR ERBB2 IL1B MMP9 PDCD1 PDCD1LG2
11 normal MP:0002873 9.76 EGFR ERBB2 FLT1 KDR PAK1 SERPINB5
12 respiratory system MP:0005388 9.56 CLDN18 EGFR ERBB2 KDR MMP9 PAK1
13 skeleton MP:0005390 9.36 CD274 CLDN18 EGFR ERBB2 IL1B KDR

Drugs & Therapeutics for Gastroesophageal Junction Adenocarcinoma

Drugs for Gastroesophageal Junction Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
2
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
3
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
4
leucovorin Approved Phase 3 58-05-9 6006 143
5
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
6
nivolumab Approved Phase 2, Phase 3 946414-94-4
7
Ipilimumab Approved Phase 2, Phase 3 477202-00-9
8
Pembrolizumab Approved Phase 3 1374853-91-4
9
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054
10
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
11
Fluorouracil Approved Phase 3 51-21-8 3385
12
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
13
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
14
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
15
Epirubicin Approved Phase 3 56420-45-2 41867
16
Trastuzumab Approved, Investigational Phase 2, Phase 3 180288-69-1 9903
17
Adenosine Approved, Investigational Phase 2, Phase 3 58-61-7 60961
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
19
Rilotumumab Investigational Phase 3 872514-65-3
20 topoisomerase I inhibitors Phase 3
21 Central Nervous System Stimulants Phase 3
22 Analgesics Phase 3
23 Antiemetics Phase 3
24 Opiate Alkaloids Phase 3
25 Trace Elements Phase 3
26 Micronutrients Phase 3
27 Vitamins Phase 3
28 Antidotes Phase 3
29 Vitamin B Complex Phase 3
30 Immunosuppressive Agents Phase 2, Phase 3
31 Nutrients Phase 3
32 Folate Phase 3
33 Protective Agents Phase 3
34 Calcium, Dietary Phase 3
35 Vitamin B9 Phase 3
36 Hematinics Phase 3
37
Apatinib Phase 3 811803-05-1
38 Pharmaceutical Solutions Phase 3
39 Mitogens Phase 3
40 Albumin-Bound Paclitaxel Phase 2, Phase 3
41 Tubulin Modulators Phase 2, Phase 3
42 Antimetabolites Phase 3
43 Antimitotic Agents Phase 2, Phase 3
44 Immunoglobulins, Intravenous Phase 3
45 Antineoplastic Agents, Immunological Phase 3
46 Anti-Bacterial Agents Phase 3
47 Antibiotics, Antitubercular Phase 3
48 Immunoglobulin G Phase 3
49 taxane Phase 2, Phase 3
50 Ado-trastuzumab emtansine Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 170)
# Name Status NCT ID Phase Drugs
1 A Randomized, Multicenter Study To Evaluate The Efficacy And Safety Of Apatinib Versus Docetaxel In Patients With Previously Treated Locally Advanced Or Metastatic Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction Unknown status NCT02409199 Phase 2, Phase 3 Docetaxel;apatinib
2 Phase Ⅱ/Ⅲ Study of Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma Unknown status NCT02193594 Phase 2, Phase 3 Adjuvant chemotherapy
3 Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Gefitinib (Iressa®) Versus Placebo in Esophageal Cancer Progressing After Chemotherapy Completed NCT01243398 Phase 3
4 A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT02625623 Phase 3 Avelumab;Irinotecan;Paclitaxel
5 A Randomized, Open, Multi-center, Phase III Study of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients Completed NCT01824459 Phase 3 S-1;Oxaliplatin;Cisplatin
6 Randomised Phase III Study of Docetaxel vs Active Symptom Control in Patients With Relapsed Oesophago-gastric Adenocarcinoma Completed NCT00978549 Phase 3 docetaxel;steroid therapy
7 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT02545504 Phase 3 Andecaliximab;Placebo;Leucovorin;5-fluorouracil;Oxaliplatin
8 A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine Completed NCT01170663 Phase 3 Placebo;Paclitaxel
9 A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy Completed NCT00917384 Phase 3 Placebo
10 Open-label, Randomized, Controlled, Multicenter Phase III Study Investigating Cetuximab in Combination With Capecitabine (Xeloda, X) and Cisplatin (P) Versus XP Alone as First-line Treatment for Subjects With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction Completed NCT00678535 Phase 3 Cetuximab;Capecitabine;Cisplatin
11 A Phase III Clinical Trial of BBI608 Plus Weekly Paclitaxel vs. Placebo Plus Weekly Paclitaxel in Adult Patients With Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma Completed NCT02178956 Phase 3 BBI608;Paclitaxel
12 Multimodal Therapy With and Without Cetuximab in Patients With Locally Advanced Esophageal Carcinoma - An Open-Label Phase III Trial Completed NCT01107639 Phase 3 cisplatin;docetaxel
13 Open Label, Randomised, Multicenter Phase III Study of Adjuvant Chemotherapy in Radically Resected Adenocarcinoma of the Stomach or Gastroesophageal Junction: Comparison of a Sequential Treatment (CPT-11+5-FU/LV --> TXT+CDDP) Versus a 5-FU/LV Regimen Completed NCT01640782 Phase 3 Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin;Leucovorin, 5-Fluorouracil
14 RACE-trial: Neoadjuvant Radiochemotherapy Versus Chemotherapy for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) A Randomized Phase III Joint Study of the AIO, ARO and DGAV Recruiting NCT04375605 Phase 3 5-Fluorouracil;Calcium folinate;Oxaliplatin;Docetaxel;Oxaliplatin during radiotherapy;5-Fluorouracil during radiotherapy
15 Prospective, Randomized, Controlled, Multicenter, Phase III Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ,III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction Recruiting NCT03986385 Phase 3 Apatinib Capecitabine Oxaliplatin;Capecitabine Oxaliplatin
16 A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine Recruiting NCT02898077 Phase 3 Ramucirumab;Paclitaxel;Placebo
17 A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma Recruiting NCT03604991 Phase 2, Phase 3 Carboplatin;Paclitaxel
18 Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05) Recruiting NCT01917552 Phase 3 capecitabine
19 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Recruiting NCT03777657 Phase 3 Tislelizumab (BGB-A317) combined with oxaliplatin and capecitabine or Tislelizumab (BGB-A317) combined with Cisplatin and 5-FU;Placebo combined with oxaliplatin and capecitabine or Placebo combined with Cisplatin and 5-FU
20 Effect of Chemotherapy Alone vs. Chemotherapy Followed by Surgical Resection on Survival and Quality of Life in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction - A Phase III Trial of Arbeitsgemeinschaft Internistische Onkologie/Chirurgische Arbeitsgemeinschaft Onkologie/Chirurgische Arbeitsgemeinschaft für Den Oberen Gastrointestinaltrakt (AIO/CAO-V/CAOGI) Recruiting NCT02578368 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Trastuzumab;sodium folinate
21 A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Recruiting NCT03504397 Phase 3 zolbetuximab;placebo;oxaliplatin;folinic acid;fluorouracil
22 A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811) Recruiting NCT03615326 Phase 3 Cisplatin;5-FU;Oxaliplatin;Capecitabine;S-1
23 Efficacy and Safety Study of the Combined Modality Therapy in Patients With Potentially Resectable, Locally Advanced Adenocarcinoma of the Esophago-gastric Junction With Preoperative Chemo- and Chemoradiation Followed by Surgical Resection Recruiting NCT01523015 Phase 2, Phase 3
24 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL) Active, not recruiting NCT02314117 Phase 3 Ramucirumab;Capecitabine;Cisplatin;Placebo;Fluorouracil
25 A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine Active, not recruiting NCT02370498 Phase 3 paclitaxel
26 Phase II Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Concurrent Radiotherapy in Patients With Potentially Resectable Adenocarcinoma of Gastroesophageal Cancer Active, not recruiting NCT01962246 Phase 2, Phase 3 Oxaliplatin; Capecitabine
27 A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine Active, not recruiting NCT03019588 Phase 3 Paclitaxel
28 A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib Active, not recruiting NCT00680901 Phase 3 Lapatinib;Placebo;Capecitabine;Oxaliplatin
29 A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel for Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine Not yet recruiting NCT04435652 Phase 2, Phase 3 QL1604;Nab-paclitaxel;Paclitaxel
30 A Study of Camrelizumab (SHR-1210) Combined With Apatinib Versus Paclitaxel or Irinotecan in Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma Progressed After First-line Chemotherapy Not yet recruiting NCT04342910 Phase 3 camrelizumab;Apatinib Mesylate;Paclitaxel;Irinotecan
31 The Efficacy and Safety of Postoperative Chemotherapy With Docetaxel Plus Oxaliplatin and Capecitabine Versus Oxaliplatin Plus Capecitabine for Postoperative Pathological Stage IIIB/IIIC Gastric Adenocarcinoma: a Randomised, Phase 3 Trial Not yet recruiting NCT04351867 Phase 3 docetaxel plus oxaliplatin and capecitabine;oxaliplatin plus capecitabine
32 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma Terminated NCT02137343 Phase 3 Rilotumumab;Placebo;Cisplatin;Capecitabine
33 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma Terminated NCT01697072 Phase 3 Rilotumumab;Epirubicin;Cisplatin;Capecitabine
34 A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction Terminated NCT01641939 Phase 2, Phase 3 Taxane;trastuzumab emtansine;trastuzumab emtansine
35 A Phase II Trial to Assess the Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT01379807 Phase 2 panitumumab + docetaxel + cisplatino
36 Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT02525237 Phase 2 Apatinib;S-1
37 Phase II Trial of Raltitrexed and Paclitaxel as Second-line Chemotherapy for Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT03083613 Phase 2 Raltitrexed;Paclitaxel
38 Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT00763646 Phase 2 Taxotere, Cisplatin, and 5-FU
39 A Prospective Study of the Efficacy and Safety of Apatinib Monotherapy as First-Line Treatment in Elderly Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT03219593 Phase 2 Apatinib mesylate tablets
40 Phase I/IIa, Single-Arm, Open Study of Apatinib and MASCT in Patients With Advanced Solid Tumors Unknown status NCT02844881 Phase 1, Phase 2 Apatinib
41 Phase I/IIa, Single-Arm, Open Study of Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma Unknown status NCT02848794 Phase 1, Phase 2 Apatinib and Irinotecan
42 Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma Completed NCT00084617 Phase 2 oxaliplatin;irinotecan hydrochloride;capecitabine
43 A Multicenter, Open-Label, Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT00084604 Phase 2 irinotecan hydrochloride;cisplatin
44 A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (With the Potential for Crossover) for Elderly and/or Poor Performance Status Patients With Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction Completed NCT00891878 Phase 2 capecitabine;sunitinib malate
45 Trial Evaluating the Efficacy and Tolerance of Perioperative Chemotherapy With 5FU-Cisplatin-Cetuximab in Adenocarcinomas of the Stomach and Gastroesophageal Junction. Phase II Single Arm, Multicenter. Completed NCT01360086 Phase 2 cisplatin;fluorouracil;leucovorin calcium
46 A Phase II Study to Evaluate Overall Response Rate of BAY 43-9006 (Sorafenib) Combined With Docetaxel and Cisplatin or Oxaliplatin in the Treatment of Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma Completed NCT00253370 Phase 2 BAY 43-9006;docetaxel;cisplatin
47 A Randomized Phase II Multicenter, Open-Label Study Evaluating the Efficacy and Safety of IMAB362 in Combination With the EOX (Epirubicin, Oxaliplatin, Capecitabine) Regimen as First-Line Treatment of Patients With CLDN18.2-Positive Advanced Adenocarcinomas of the Stomach, the Esophagus or the Gastroesophageal Junction Completed NCT01630083 Phase 2 epirubicin;oxaliplatin;capecitabine;zolbetuximab
48 A Phase 1b/2 Study of MEDI4736 in Combination With Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects With Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT02340975 Phase 1, Phase 2
49 Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT02514551 Phase 2 Ramucirumab;Paclitaxel
50 Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT02443883 Phase 2 Ramucirumab

Search NIH Clinical Center for Gastroesophageal Junction Adenocarcinoma

Genetic Tests for Gastroesophageal Junction Adenocarcinoma

Anatomical Context for Gastroesophageal Junction Adenocarcinoma

MalaCards organs/tissues related to Gastroesophageal Junction Adenocarcinoma:

40
Lymph Node, Breast, Endothelial, Lung, T Cells, Liver, Brain

Publications for Gastroesophageal Junction Adenocarcinoma

Articles related to Gastroesophageal Junction Adenocarcinoma:

(show top 50) (show all 347)
# Title Authors PMID Year
1
Relevant issues in tumor regression grading of histopathological response to neoadjuvant treatment in adenocarcinomas of the esophagus and gastroesophageal junction. 61
32141500 2020
2
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. 61
32469182 2020
3
Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma. 61
32561664 2020
4
Baseline neutrophil-lymphocyte ratio holds no prognostic value for esophageal and junctional adenocarcinoma in patients treated with neoadjuvant chemotherapy. 61
31676907 2020
5
Rare Esophageal Leptomeningeal Metastases Detected on 18F-FDG PET/CT. 61
31977493 2020
6
Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma-experience at two centres. 61
32399277 2020
7
Preoperative Chemoradiation versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma. 61
32289300 2020
8
Adverse events and management of apatinib in patients with advanced or metastatic cancers: A review. 61
32266817 2020
9
Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. 61
32347396 2020
10
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. 61
32167861 2020
11
Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment. 61
32040809 2020
12
SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). 61
31989475 2020
13
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. 61
31676670 2020
14
Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study. 61
31721447 2020
15
Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. 61
31802410 2020
16
Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population. 61
32256703 2020
17
Paraneoplastic Leukemoid Reaction in Gastroesophageal Junction Adenocarcinoma: A Case Report. 61
32001665 2020
18
S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature. 61
31895837 2020
19
Cancer-Related Pneumopericardium: A Case Report and Literature Review. 61
32110216 2020
20
Endoscopic vacuum assisted closure of esophagogastric anastomosis dehiscence: A case report. 61
31942233 2020
21
The expressions and prognostic implications of Twist and E-cadherin in adenocarcinomas of the gastroesophageal junction and proximal gastric carcinoma. 61
31876727 2019
22
The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study. 61
30671799 2019
23
Fever of Undetermined Origin During Neoadjuvant Chemoradiotherapy of Gastroesophageal Junction Adenocarcinoma Due to Radiation-induced Liver Disease. 61
31728250 2019
24
Risk factors and patterns of recurrence after curative resection in Gastroesophageal Junction Adenocarcinoma. 61
31488992 2019
25
Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma. 61
31102632 2019
26
Obturator hernia and the elderly. 61
30397870 2019
27
Minimal length of proximal resection margin in adenocarcinoma of the esophagogastric junction: a systematic review of the literature. 61
31243725 2019
28
Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer. 61
31489588 2019
29
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. 61
31142504 2019
30
Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study. 61
31234645 2019
31
High Systemic Immune-Inflammation Index is an Adverse Prognostic Factor for Patients With Gastroesophageal Adenocarcinoma. 61
31425286 2019
32
Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up. 61
31138725 2019
33
The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma. 61
30941657 2019
34
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. 61
30911859 2019
35
Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. 61
30515672 2019
36
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. 61
30913304 2019
37
Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab. 61
31410344 2019
38
Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. 61
31188215 2019
39
Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma. 61
30991863 2019
40
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. 61
31126258 2019
41
Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy. 61
30499151 2019
42
Endoscopic resection for esophageal or gastroesophageal junction adenocarcinoma. 61
31179442 2019
43
Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. 61
30470690 2019
44
Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population 61
31030487 2019
45
Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study. 61
31069184 2019
46
Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer. 61
30535535 2019
47
KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. 61
30777447 2019
48
[Multimodal therapy for gastric or gastroesophageal junction adenocarcinoma -ECF vs. FLOT]. 61
30758590 2019
49
Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. 61
30483986 2019
50
Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders. 61
30391577 2019

Variations for Gastroesophageal Junction Adenocarcinoma

Expression for Gastroesophageal Junction Adenocarcinoma

Search GEO for disease gene expression data for Gastroesophageal Junction Adenocarcinoma.

Pathways for Gastroesophageal Junction Adenocarcinoma

Pathways related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 VEGFA SNAI1 PAK1 KDR IL1B FLT1
2
Show member pathways
13.25 SNAI1 PAK1 KDR IL1B FLT1 ERBB2
3
Show member pathways
12.93 VEGFA KDR FLT1 ERBB2 EGFR
4
Show member pathways
12.9 PAK1 KDR FLT1 ERBB2 EGFR
5
Show member pathways
12.81 VEGFA PAK1 KDR FLT1 ERBB2 EGFR
6
Show member pathways
12.69 VEGFA PAK1 KDR FLT1 EGFR
7
Show member pathways
12.61 VEGFA PAK1 MMP9 KDR CLDN18
8
Show member pathways
12.57 VEGFA PAK1 KDR ERBB2 EGFR
9
Show member pathways
12.54 PDCD1 PAK1 IL1B EGFR CD274
10
Show member pathways
12.53 PAK1 IL1B ERBB2 EGFR
11 12.5 PDCD1LG2 PDCD1 IL1B CD274
12 12.47 VEGFA SERPINB5 MMP9 ERBB2 EGFR
13
Show member pathways
12.45 KDR FLT1 ERBB2 EGFR
14
Show member pathways
12.41 VEGFA PAK1 KDR FLT1 EGFR
15 12.37 VEGFA PAK1 KDR IL1B FLT1 ERBB2
16
Show member pathways
12.36 VEGFA KDR FLT1 EGFR
17
Show member pathways
12.35 PAK1 KDR FLT1 ERBB2 EGFR
18
Show member pathways
12.3 KDR IL1B FLT1 ERBB2 EGFR
19
Show member pathways
12.23 VEGFA PAK1 KDR FLT1 EGFR
20
Show member pathways
12.21 KDR IL1B FLT1 EGFR
21
Show member pathways
12.17 KDR FLT1 ERBB2 EGFR
22
Show member pathways
12.17 PDCD1LG2 PDCD1 PAK1 CD274
23 12.08 KDR FLT1 ERBB2 EGFR
24 12.08 PDCD1LG2 PDCD1 CLDN18 CD274
25 12.04 VEGFA MMP9 KDR IL1B
26
Show member pathways
11.93 VEGFA PAK1 KDR
27 11.92 VEGFA MMP9 IL1B
28
Show member pathways
11.89 VEGFA PAK1 KDR FLT1
29
Show member pathways
11.85 PDCD1LG2 PDCD1 PAK1 CD274
30 11.83 VEGFA FLT1 ERBB2 EGFR
31
Show member pathways
11.82 VEGFA ERBB2 EGFR
32 11.82 VEGFA IL1B FLT1
33 11.75 TAF4B SNAI1 MMP9
34 11.74 VEGFA PAK1 MMP9 KDR ERBB2 EGFR
35
Show member pathways
11.7 VEGFA PAK1 KDR FLT1
36 11.69 SNAI1 ERBB2 EGFR
37 11.67 PAK1 ERBB2 EGFR
38 11.65 SERPINB5 MMP9 KDR FLT1
39
Show member pathways
11.63 VEGFA MMP9 IL1B
40 11.57 PAK1 ERBB2 EGFR
41
Show member pathways
11.55 PAK1 MMP9 ERBB2 EGFR
42 11.49 VEGFA MMP9 ERBB2 EGFR
43
Show member pathways
11.42 VEGFA KDR EGFR
44 11.29 VEGFA KDR FLT1
45 11.19 VEGFA KDR FLT1 EGFR
46 10.92 PAK1 KDR IL1B FLT1 ERBB2 EGFR
47
Show member pathways
10.75 VEGFA KDR FLT1
48 10.3 VEGFA MMP9 KDR FLT1

GO Terms for Gastroesophageal Junction Adenocarcinoma

Cellular components related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 8.92 KDR FLT1 ERBB2 EGFR

Biological processes related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.12 VEGFA SNAI1 PDCD1 KDR FLT1 ERBB2
2 protein phosphorylation GO:0006468 10.05 PAK1 KDR FLT1 ERBB2 EGFR
3 negative regulation of apoptotic process GO:0043066 10.02 VEGFA PDCD1 MMP9 KDR EGFR
4 cell surface receptor signaling pathway GO:0007166 9.96 PDCD1LG2 ERBB2 EGFR CD274
5 MAPK cascade GO:0000165 9.93 PAK1 IL1B ERBB2 EGFR
6 cell migration GO:0016477 9.92 SNAI1 PAK1 KDR FLT1
7 positive regulation of angiogenesis GO:0045766 9.85 VEGFA KDR IL1B FLT1
8 peptidyl-tyrosine phosphorylation GO:0018108 9.84 KDR FLT1 ERBB2 EGFR
9 wound healing GO:0042060 9.82 PAK1 ERBB2 EGFR
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.81 VEGFA PAK1 EGFR
11 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.8 KDR FLT1 ERBB2 EGFR
12 positive regulation of epithelial cell proliferation GO:0050679 9.78 VEGFA ERBB2 EGFR
13 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.77 VEGFA KDR FLT1
14 positive regulation of T cell proliferation GO:0042102 9.77 PDCD1LG2 IL1B CD274
15 positive regulation of cell proliferation GO:0008284 9.76 VEGFA PAK1 MTA3 KDR IL1B FLT1
16 positive regulation of kinase activity GO:0033674 9.73 KDR FLT1 ERBB2 EGFR
17 protein autophosphorylation GO:0046777 9.72 PAK1 KDR FLT1 ERBB2 EGFR
18 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.7 VEGFA KDR FLT1
19 sprouting angiogenesis GO:0002040 9.69 VEGFA KDR FLT1
20 positive regulation of MAP kinase activity GO:0043406 9.67 VEGFA FLT1 ERBB2 EGFR
21 astrocyte activation GO:0048143 9.66 IL1B EGFR
22 negative regulation of activated T cell proliferation GO:0046007 9.66 PDCD1LG2 CD274
23 negative regulation of interleukin-10 production GO:0032693 9.65 PDCD1LG2 CD274
24 regulation of ERK1 and ERK2 cascade GO:0070372 9.65 IL1B ERBB2 EGFR
25 positive regulation of positive chemotaxis GO:0050927 9.64 VEGFA KDR
26 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.63 VEGFA IL1B FLT1
27 vascular wound healing GO:0061042 9.61 VEGFA KDR
28 negative regulation of ERBB signaling pathway GO:1901185 9.58 ERBB2 EGFR
29 vascular endothelial growth factor signaling pathway GO:0038084 9.58 VEGFA KDR FLT1
30 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.57 VEGFA KDR
31 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.56 VEGFA KDR
32 T cell costimulation GO:0031295 9.56 PDCD1LG2 PDCD1 PAK1 CD274
33 positive regulation of protein phosphorylation GO:0001934 9.5 VEGFA PAK1 MMP9 KDR IL1B ERBB2
34 positive regulation of cell migration GO:0030335 9.28 VEGFA SNAI1 PAK1 MMP9 KDR IL1B

Molecular functions related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.77 PAK1 KDR FLT1 ERBB2 EGFR
2 growth factor binding GO:0019838 9.33 KDR FLT1 ERBB2
3 vascular endothelial growth factor binding GO:0038085 9.32 KDR FLT1
4 vascular endothelial growth factor-activated receptor activity GO:0005021 9.26 KDR FLT1
5 protein tyrosine kinase activity GO:0004713 9.26 KDR FLT1 ERBB2 EGFR
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.92 KDR FLT1 ERBB2 EGFR

Sources for Gastroesophageal Junction Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....